MedPath

Nazartinib

Generic Name
Nazartinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C26H31ClN6O2
CAS Number
1508250-71-2
Unique Ingredient Identifier
KE7K32EME8
Background

Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations).

Associated Conditions
-
Associated Therapies
-
nature.com
·

Recent advances in targeting the “undruggable” proteins

Covalent inhibitors bind to target proteins via covalent bonds, offering sustained inhibition and longer residence times compared to non-covalent inhibitors. They are effective against undruggable proteins and mutated kinases, exemplified by nirmatrelvir in COVID-19 treatment and sotorasib for KRASG12C mutations. Covalent inhibitors like sotorasib and adagrasib have shown promise in treating cancers with KRAS mutations, overcoming resistance and expanding therapeutic options.

Related Clinical Trials:

© Copyright 2025. All Rights Reserved by MedPath